Boehringer Ingelheim

This study looked at whether a medicine called Avenciguat could lower high blood pressure in the main vein to the liver in adults with cirrhosis. Participants took either a low or high dose of the drug or a placebo twice a day for 24 weeks. The trial was terminated early, so resu…

This study tested a new pill, BI 907828, in adults with advanced cancers of the bile duct, pancreas, lung, or bladder that have a specific genetic change (MDM2 amplification). The goal was to see if the drug could shrink tumors. The study was stopped early, but the results may st…

This study tested a medicine called spesolimab in people aged 12 and older with Netherton syndrome, a rare genetic skin condition causing redness and scaling. Participants received either the drug or a placebo for 4 months, then everyone could get the drug. The goal was to see if…

This study looks at the long-term safety of spesolimab for people with palmoplantar pustulosis (PPP), a skin condition causing painful blisters on hands and feet. Participants who benefited from spesolimab in earlier studies continue monthly injections for up to 5 years. Doctors …

This study tested an experimental drug called BI 1839100 to see if it could reduce chronic coughing in adults with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). Participants took different doses of the drug or a placebo for 12 weeks. Coughing was me…

This early-stage study looked at a new drug called BI 3009947 in 40 healthy men. The goal was to check its safety and how the body absorbs it. The study also compared two different pill versions and tested the effect of food. The trial was terminated early, so results are limited…

This early-phase study used special PET scans to track an experimental drug (BI 754111) in patients with advanced lung or head/neck cancer. The goal was to see where the drug goes in the body and how much reaches tumors. Only 8 patients were enrolled before the study was stopped …